在癌症中的PI3K/AKT/mTOR信号转导通路和向疗法
Antonino Glaviano1, Aaron S C Foo2, Hiu Y Lam3,4
1Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo, 90123, Palermo, Italy.
PI3K/AKT/mTOR (PAM) 途径驱动癌症生长和治疗耐药性. 针对这种途径的抑制剂在临床试验中显示出克服耐药性的希望,尽管耐药性机制仍然存在.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 细胞信号传递 细胞信号传递
背景情况:
- PI3K/AKT/mTOR (PAM) 途径调节细胞生存,生长和进展.
- PAM轴的调节失调在人类癌症中很常见,并且与治疗耐药性有关.
- PI3K,PTEN损失和AKT功能增加的过度活跃会导致癌症的进展和抵抗.
研究的目的:
- 审查癌症中PAM通路的主要失调.
- 讨论PAM抑制剂在临床试验中克服治疗耐药性的疗效.
- 探索对PAM向治疗的耐药性机制,包括免疫学和免疫治疗中的作用.
主要方法:
- 关于癌症中PAM信号通路失调的文献综述.
- 对PI3K,AKT和mTOR抑制剂作为单疗法和组合治疗的临床试验数据的分析.
- 检查对PAM向疗法的耐药性机制.
主要成果:
- 在癌症中,PAM轴经常被激活,并与对治疗的耐药性有关.
- 在临床试验中,PAM抑制剂单独或与其他药物一起显示出克服耐药性的潜力.
- 了解耐药机制对于有效的癌症治疗策略至关重要.
结论:
- 向PAM通路是癌症治疗开发中的关键策略.
- 对抗性机制的进一步研究,包括与免疫学和免疫治疗的相互作用,是必不可少的.
- 需要组合疗法和新的策略来克服癌症中PAM驱动的耐药性.
更多相关视频
07:39Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The JAK-STAT Signaling Pathway
MAPK Signaling Cascades
